The SACHI trial is a phase 3 multicenter, open-label, randomized controlled trial that enrolled 211 patients with advanced EGFR-mutation positive and MET-amplified non-small cell lung cancer (NSCLC) in China who had progressed after first-line EGFR TKI therapy.[1][2][7] Patients were randomized 1:1 to the combination of savolitinib plus osimertinib (n=106) or platinum-based chemotherapy (pemetrexed plus cisplatin or carboplatin, n=105).[1][2][7] The primary endpoint was investigator-assessed progression-free progression (PFS), where median PFS was 8.2 months (95% CI 6.9–11.2) in the combination group versus 4.5 months (95% CI 3.0–5.4) in the chemotherapy group (HR 0.34; 95% CI 0.23–0.49; p<0.0001).[1][2][3] The objective response rate (ORR) was 58% in the savolitinib plus osimertinib group versus 34% in the chemotherapy group.[1][2][3] Disease control rate (DCR) was 89% vs. 67% and median duration of response (DoR) was 8.4 months vs. 3.2 months.[1][2][3] The combination showed a favorable tolerability profile, with equal incidence of grade 3 and higher serious adverse events (57% in both groups).[3] An independent monitoring committee confirmed the achievement of the primary objective in January 2025 and ended patient recruitment.[1]